A leaky blood-brain barrier has long been implicated in cognitive dysfunction in aging and neurodegeneration, but reliable human data were lacking. Here, Montagne et al. (2015) provide the first in vivo evidence of blood-brain barrier disruption in the aging hippocampus and in minimal cognitive impairment.
Over 100 years ago, Paul Ehrlich discovered serendipitously that the brain of animals injected in the bloodstream with a blue dye was not stained blue like other organs, and that dyes injected directly into the brain did not reach the bloodstream (Hawkins and Davis, 2005) . This fundamental observation led to the realization that the brain is shielded by a seemingly impenetrable barrier, the blood-brain barrier (BBB). Central to the BBB are unique features of cerebral endothelial cells, which are adjoined and sealed by specialized junctions (tight junctions, TJ) and exhibit minimal vesicular transport (transcytosis) preventing the passage of hydrophilic molecules from blood to brain and vice versa (Obermeier et al., 2013) . Rather, an intricate system of transporters regulates the bidirectional traffic of substances across the barrier according to the metabolic needs of the brain (Neuwelt et al., 2011) . Owing to its critical role in safeguarding the homeostasis of the brain's microenvironment, it has long been postulated that alterations in the BBB may partake in brain diseases, including the cognitive dysfunction associated with aging and Alzheimer's dementia (AD) (Zlokovic, 2008) . However, due to the lack of suitable methods to assess BBB integrity quantitatively and regionally in the human brain in vivo, it has been challenging to demonstrate disruptions of the BBB affecting brain regions involved in cognition. In this issue of Neuron, Montagne et al., (2015) provide the most direct evidence to date of BBB disruption restricted to the hippocampus in aging and in patients with minimal cognitive impairment (MCI), who are at increased risk for AD. The findings provide a glimpse into a previously unrecognized determinant of hippocampal dysfunction in humans and suggest novel biomarkers and therapeutic targets for cognitive dysfunction.
Some studies of the BBB in aging and dementia have relied on autopsy material in which the extravasation of plasma proteins, such as albumin or fibrinogen, was detected qualitatively in selected brain regions by immunocytochemistry (Zlokovic, 2008) . Other studies have used the concentration ratio of albumin in cerebrospinal fluid (CSF) and plasma as a more quantitative index of BBB permeability. Since albumin does not normally cross the BBB, increased CSF concentrations suggest BBB disruption (Rosenberg, 2012) . However, these approaches are not ideal: in post-mortem brains, tissue degradation, advanced disease, and coexisting pathologies complicate establishing cause-effect relationships, while the CSF/plasma albumin ratio cannot pinpoint the site(s) of BBB disruption. More recently, imaging methods based on the brain penetration of gadolinium, a contrast agent used in magnetic resonance imaging (MRI), have been introduced (Rosenberg, 2012) , but the resolution of the images was not sufficient to detect BBB changes in regions involved in cognitive processing, such as the hippocampus. Building on these previous imaging studies, Montagne et al. developed a high-resolution MRI method to simultaneously map the blood-to-brain transfer constant of gadolinium (K trans ) regionally and quantitatively, and with a resolution sufficient to image discrete regions of the hippocampus. Using this approach, they generated K trans brain maps in cognitively normal individuals at different ages (23 to 91 years), and in patients with MCI. In the hippocampus, mainly CA1 and dentate gyrus, they found that K trans increases linearly with age. In subjects with MCI, however, the K trans increases were about 60% larger than those seen in cognitively intact age matched controls. These increases in permeability were not associated with reduced hippocampal volume, suggesting that they preceded the development of tissue damage and hippocampal atrophy. Supporting the validity of the method, in cognitively intact subjects with multiple sclerosis, the K trans increases were present only in the white matter, where BBB disruption is well described (Zlokovic, 2008) . These observations provide the first direct evidence for an age-dependent and regionally selective disruption of the BBB in the hippocampus of cognitively normal individuals, which is exacerbated in MCI.
To gain a mechanistic insight into the processes underlying the BBB alterations, the authors also examined CSF biomarkers of BBB permeability and vascular damage. Hippocampal K trans was well correlated with an increase in CSF/plasma albumin ratio, but not with markers of inflammation and neuronal or endothelial damage, nor with enzymes involved in BBB disruption, such as metalloproteinase-9 (MMP9) (Zlokovic, 2008) . Interestingly, a strong association was observed between the increase in K trans and the levels of the soluble form of the platelet growth factor receptor-b (PDGFRb), a receptor enriched in pericytes. Pericytes are contractile vascular cells enveloped by the endothelial basement membrane of capillaries and particularly abundant in brain (Armulik et al., 2011) . Recent evidence indicates that pericytes are critical for the development and maintenance of the BBB and may even regulate microvascular blood flow (Armulik et al., 2011; Hall et al., 2014) . Montagne et al. demonstrated that pericytes in culture shed PDGFRb in conditions of severe hypoxia or exposure to high concentrations of amyloid-b (Ab), a key pathogenic factor in AD. They also observed increases in CSF PDGFRb in mouse models with BBB leakage due to pericyte damage. On these bases, it is conceivable that the increase in PDGFRb found in aged individuals and MCI reflects pericyte damage, which, in turn, may underlie the disruption of the BBB (Figure 1 ). Further studies validating CSF PDGFRb as a marker of cerebrovascular health would be important to assess its usefulness as a research tool and disease biomarker.
How does gadolinium cross the BBB? Since gadolinium tends to bind to plasma proteins, the assessment of the BBB using this contrast medium reflects brain entry of relatively large molecules. Therefore, the blood-to-brain transfer is likely to be mediated by bulk flow through leaky TJ or increased transcytosis. MMP9, a proteolytic enzyme involved in basement membrane and TJ disruption in ischemic injury (Iadecola, 2013) , was not increased in the CSF, suggesting that massive vascular damage may not play a role. However, it would be of interest to also examine MMP2, which has been more directly linked to the BBB leakage associated with cognitive impairment (Rosenberg, 2012) . If pericyte damage is involved, a likely mechanism is increased bulk flow transcytosis (Armulik et al., 2011) . Pericyte may regulate vesicular transport by inducing the expression of the major facilitator super family domain containing 2a (mfsd2a) in endothelial cells, which suppresses vesicular transport (Ben-Zvi et al., 2014) . Accordingly, pericyte loss could reduce the endothelial expression of mfsd2a, resulting in increased transcytosis and gadolinium transport across the BBB (Figure 1 ). On the other hand, since pericytes have also been implicated in TJ stabilization (Armulik et al., 2011) , entry of gadolinium through leaky TJ cannot be ruled out.
What causes the age-dependent BBB disruption and preferential localization to the hippocampus? Since the hippocampus and entorhinal cortex are sites of early pathology in aging and AD (Braak and Braak, 1991) , it is reasonable to speculate that Ab or tau could have a role. While tau cannot be completely excluded, Ab accumulates earlier than tau, is toxic to pericytes (Verbeek et al., 1997) , and can induce cerebral endothelial dysfunction, including increased BBB permeability, by activation of transient receptor potential melastatin-2 channels (TRPM-2) and dysregulation of endothelial intracellular Ca 2+ (Park et al., 2014) . Another question concerns how a leaky BBB in the hippocampus promotes cognitive decline. Several mechanisms could be involved, including entry of toxins and plasma proteins (hemosiderin, thrombin, plasmin), ionic imbalance, activation of microglia, and cytokine production (Obermeier et al., 2013; Neuwelt et al., 2011) . The study of Montagne et al. suggests that the hippocampus can tolerate a certain degree of BBB dysfunction with no impact on cognitive performance. Thus, in normal aging there is a robust increase in BBB permeability without impaired cognition, whereas in MCI the BBB disruption, albeit more pronounced, is associated with cognitive impairment. It remains unclear what tips the balance toward impaired cognition. Although ''cognitive reserves'' may allow certain individuals to tolerate more pathology before exhibiting cognitive decline, one possibility is that the hippocampal dysfunction caused by the BBB alteration is compensated up to a certain level, which, when exceeded, results in cognitive impairment. Another possibility is that the BBB disruption alone is not sufficient to induce hippocampal dysfunction, and that concomitant pathogenic factors intrinsic to the hippocampus are also needed. For example, as stated above, Ab could damage pericytes and endothelial cells leading to the BBB disruption (Figure 1 ). In turn, the BBB disruption and pericyte loss could alter the brain clearance of Ab and promote Ab accumulation and tau hyperphosphorylation (Sagare et al., 2013) , factors well known to exert Ab damages pericytes leading to suppression of mfsd2a expression in endothelial cells and increased endothelial vesicular transport. Ab also causes endothelial Ca 2+ overload through activation of TRPM2 channels, which contributes to the BBB disruption. Vascular damage reduces Ab clearance and promotes tau phosphorylation. The alteration in homeostasis caused by the BBB disruption, in concert with the deleterious effects of Ab and tau on synaptic function, may result in hippocampal dysfunction and cognitive deficits. direct toxic effects on synapses leading to hippocampal dysfunction (Spires-Jones and Hyman, 2014) (Figure 1) . Recently introduced methods for amyloid and tau imaging in humans could provide insight into the interaction between AD pathology and BBB disruption (Spires-Jones and Hyman, 2014).
Owing to the cross-sectional design of the study, the evolution in space and time of the BBB alterations could not be assessed in individual subjects. Although Montagne et al. focused on cognitively normal or mildly affected subjects, it would be of instructive to examine the spatiotemporal evolution of the BBB alterations in MCI patients who go on to develop frank AD. Recent data indicate that AD pathology and the associated synaptic dysfunction spread throughout the brain according to a stereotyped pattern, largely reflecting neuronal connectivity (Spires-Jones and Hyman, 2014). It would be informative to determine if the BBB alteration follows a similar progression and, if so, whether it precedes or follows the spread of amyloid and tau.
Another question concerns the role of BBB disruption in white matter pathology. Subcortical white matter lesions, assumed to be on ischemic bases, are common in older subjects and are an important correlate of cognitive decline in aging, MCI, and AD (Iadecola, 2013) . Although less pronounced than in the hippocampus, Montagne et al. observed a trend for increased permeability in the white matter, especially in MCI, raising the possibility that BBB leakage and not ischemia is an early determinant of white matter damage. Using their highresolution imaging method, it would be feasible for the first time to determine if BBB leakage precedes white matter damage, which is still unsettled in the literature (Iadecola, 2013 
